New drug duo shows promise for tough lung cancer
NCT ID NCT06532032
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 1/2 trial tested a combination of two drugs, amivantamab and docetaxel, in 12 people with advanced non-small cell lung cancer that had spread. The goal was to find a safe dose and see if the combo could shrink tumors. The study focused on patients whose cancer had worsened after standard treatments like chemotherapy and immunotherapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Amivantamab and docetaxel
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced non-small cell lung cancer that has stopped responding to standard therapies.
What could go wrong
This is an early-phase trial with only 12 participants, so results may not apply to everyone. Side effects can be serious, including severe toxicity and lung inflammation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ankara Bilkent Sehir Hastanesi
Çankaya, 06800, Turkey (Türkiye)
-
Cancer and Blood Specialty Clinic
Los Alamitos, California, 90720, United States
-
Changhua Christian Hospital
Changhua, 500, Taiwan
-
Chi Mei Medical Center Liu Ying
Liou Ying Township, 736, Taiwan
-
Hunterdon Hematology Oncology
Flemington, New Jersey, 08822, United States
-
Kaohsiung Medical University Hospital
Kaohsiung City, 80708, Taiwan
-
Leeds Teaching Hospitals NHS Trust
Leeds, LS9 7TF, United Kingdom
-
National Taiwan University Hospital
Taipei, 10043, Taiwan
-
Oncology Hematology Associates
Springfield, Missouri, 65807, United States
-
Taichung Veterans General Hospital
Taichung, 40705, Taiwan
-
Taipei Medical University
Taipei, 110, Taiwan
-
The Royal Marsden NHS Trust
Sutton, SM2 5PT, United Kingdom
-
UCI Health Irvine Hospital
Irvine, California, 92612, United States
-
University of California Irvine Medical Center Chao Family Comprehensive Cancer Center
Orange, California, 92868, United States
-
Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States